CAWM
TEVA icon

Capital A Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Capital A Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-27,264
Closed -$419K – 799
2025
Q1 		$419K Buy
27,264
+231
+0.9% +$4.13K 0.44% 27
2024
Q4 		$596K Buy
+27,033
New +$492K 0.99% 20

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Capital A Wealth Management's TEVA Position: Q2 2025 in Review

Capital A Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 27,264 shares — an estimated $419K sold.

Capital A Wealth Management first reported a position in TEVA in Q4 2024 and held it in 2 quarters. The position peaked at $596K in Q4 2024. 540 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Capital A Wealth Management reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Capital A Wealth Management sold 27,264 Teva Pharmaceuticals shares in Q2 2025, an estimated $419K.
  • Capital A Wealth Management first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Capital A Wealth Management's Teva Pharmaceuticals position peaked at $596K in Q4 2024.
  • 540 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Capital A Wealth Management's 13F filing for Q2 2025, filed 26 Sep 2025.